Praxis Precision Medicines, Inc. (PRAX)Healthcare | Biotechnology | Boston, United States | NasdaqGS
344.75 USD
-23.10
(-6.280%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 344.75 |
Hot Take ↕ | Aug. 22, 2026, 3:44 a.m. EDT
Praxis Precision Medicines is a high-risk biotech play where a fortress balance sheet masks a lack of profitability. Despite a strong analyst consensus and recent technical recovery above key moving averages, the stock has lost over 80% of its value over the past four years, reflecting deep market skepticism about its business quality. While the cash position provides a safety net, the negative earnings and free cash flow indicate ongoing burn. Options traders are positioning for continued volatility, hedging downside risks while speculating on upside breakthroughs. This is a speculative wager on future clinical milestones, not a stable investment. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.094399 |
| AutoTheta | 0.119560 |
| MSTL | 0.120585 |
| AutoETS | 0.123490 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 52% |
| H-stat | 0.11 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.144 |
| Excess Kurtosis | -0.31 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.081 |
| Market Cap | 9,625,415,680 |
| Forward P/E | -37.09 |
| Beta | 2.78 |
| Website | https://praxismedicines.com |
As of Aug. 22, 2026, 3:44 a.m. EDT: Implied volatility remains elevated across expirations, reflecting uncertainty. Open interest is concentrated at significant strikes: deep out-of-the-money calls (500+) suggest bullish speculation, while substantial put open interest at lower strikes (130-320) indicates downside hedging. The mix suggests a wide-range expectation rather than a directional bet.
| Attribute | Value |
|---|---|
| 52 Week Change | 7.0775146 |
| Address1 | 99 High Street |
| Address2 | 30th Floor |
| All Time High | 914.265 |
| All Time Low | 11.85 |
| Ask | 376.24 |
| Ask Size | 1 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 371,390 |
| Average Daily Volume3 Month | 504,974 |
| Average Volume | 504,974 |
| Average Volume10Days | 371,390 |
| Beta | 2.776 |
| Bid | 372.31 |
| Bid Size | 1 |
| Board Risk | 7 |
| Book Value | 48.038 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 344.75 |
| Current Ratio | 15.734 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 367.7 |
| Day Low | 344.69 |
| Debt To Equity | 0.081 |
| Display Name | Praxis Precision Medicines |
| Earnings Call Timestamp End | 1,786,019,400 |
| Earnings Call Timestamp Start | 1,786,019,400 |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,794,227,400 |
| Earnings Timestamp Start | 1,794,227,400 |
| Ebitda | -378,048,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -23.457 |
| Enterprise Value | 8,867,951,616 |
| Eps Current Year | -13.93524 |
| Eps Forward | -9.2938 |
| Eps Trailing Twelve Months | -12.97 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 332.809 |
| Fifty Day Average Change | 11.9410095 |
| Fifty Day Average Change Percent | 0.035879467 |
| Fifty Two Week Change Percent | 707.75146 |
| Fifty Two Week High | 392.7 |
| Fifty Two Week High Change | -47.950012 |
| Fifty Two Week High Change Percent | -0.122103415 |
| Fifty Two Week Low | 37.19 |
| Fifty Two Week Low Change | 307.56 |
| Fifty Two Week Low Change Percent | 8.269965 |
| Fifty Two Week Range | 37.19 - 392.7 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,602,855,000,000 |
| Float Shares | 24,077,360 |
| Forward Eps | -9.2938 |
| Forward P E | -37.09462 |
| Free Cashflow | -199,439,376 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 168 |
| Fullday Change | -23.1 |
| Fullday Change Percent | -6.27974 |
| Fullday Price | 344.75 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Gross Profits | -290,705,984 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0027599998 |
| Held Percent Institutions | 1.23121 |
| Implied Shares Outstanding | 27,919,988 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-10-16 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,701,216,000 |
| Last Split Factor | 1:15 |
| Long Business Summary | Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE. In addition, the company is developing product candidates in pre-clinical trial comprising PRAX-020 to treat KCNT1; PRAX-080 that targets PCDH19 mosaic expression disorders; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a cooperation and license agreement with RogCon Inc.; research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and research collaboration and license agreement to develop an iontophoretic transdermal patch for the delivery of ulixacaltamide. The company was formerly known as EpiPM Therapeutics, Inc. and changed its name to Praxis Precision Medicines, Inc. in October 2016. Praxis Precision Medicines, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts. |
| Long Name | Praxis Precision Medicines, Inc. |
| Market | us_market |
| Market Cap | 9,625,415,680 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_409236524 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -339,126,016 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 10,254,592,792 |
| Number Of Analyst Opinions | 19 |
| Open | 363.4 |
| Operating Cashflow | -305,076,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 617 300 8460 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 344.75 |
| Post Market Time | 1,787,959,804 |
| Previous Close | 367.85 |
| Price Eps Current Year | -24.739437 |
| Price Hint | 2 |
| Price To Book | 7.1766105 |
| Profit Margins | 0.0 |
| Quick Ratio | 15.462 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.47368 |
| Region | US |
| Regular Market Change | -23.1 |
| Regular Market Change Percent | -6.27974 |
| Regular Market Day High | 367.7 |
| Regular Market Day Low | 344.69 |
| Regular Market Day Range | 344.69 - 367.7 |
| Regular Market Open | 363.4 |
| Regular Market Previous Close | 367.85 |
| Regular Market Price | 344.75 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 282,849 |
| Return On Assets | -0.2565 |
| Return On Equity | -0.38862 |
| Sand P52 Week Change | 0.1966995 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 27,919,988 |
| Shares Percent Shares Out | 0.133 |
| Shares Short | 3,714,692 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 3,763,401 |
| Short Name | Praxis Precision Medicines, Inc |
| Short Percent Of Float | 0.13340001 |
| Short Ratio | 9.49 |
| Source Interval | 15 |
| State | MA |
| Symbol | PRAX |
| Target High Price | 1,201.0 |
| Target Low Price | 188.0 |
| Target Mean Price | 638.6842 |
| Target Median Price | 575.0 |
| Total Cash | 758,550,976 |
| Total Cash Per Share | 27.169 |
| Total Debt | 1,087,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -12.97 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 302.80396 |
| Two Hundred Day Average Change | 41.946045 |
| Two Hundred Day Average Change Percent | 0.13852543 |
| Type Disp | Equity |
| Volume | 282,849 |
| Website | https://praxismedicines.com |
| Zip | 2,110 |